Giuseppina Andreotti
Overview
Explore the profile of Giuseppina Andreotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
622
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Monticelli M, Mele B, Andreotti G, Cubellis M, Riccio G
Eur J Med Genet
. 2021 Apr;
64(6):104227.
PMID: 33872774
The identification of high-risk factors for the infection by SARS-CoV-2 and the negative outcome of COVID-19 is crucial. The genetic background of the host might account for individual responses to...
12.
Dessi A, Peluso P, Dallocchio R, Weiss R, Andreotti G, Allocca M, et al.
Molecules
. 2020 May;
25(9).
PMID: 32397334
The 3,3',5,5'-tetrachloro-2-iodo-4,4'-bipyridine structure is proposed as a novel chemical scaffold for the design of new transthyretin (TTR) fibrillogenesis inhibitors. In the frame of a proof-of-principle exploration, four chiral 3,3',5,5'-tetrachloro-2-iodo-2'-substituted-4,4'- bipyridines...
13.
Liguori L, Monticelli M, Allocca M, Mele B, Lukas J, Cubellis M, et al.
Int J Mol Sci
. 2020 Jan;
21(2).
PMID: 31940970
The term "pharmacological chaperone" was introduced 20 years ago. Since then the approach with this type of drug has been proposed for several diseases, lysosomal storage disorders representing the most...
14.
Seemann S, Ernst M, Cimmaruta C, Struckmann S, Cozma C, Koczan D, et al.
Biochem J
. 2020 Jan;
477(2):359-380.
PMID: 31899485
The lysosomal storage disorder Fabry disease is characterized by a deficiency of the lysosomal enzyme α-Galactosidase A. The observation that missense variants in the encoding GLA gene often lead to...
15.
Monticelli M, Liguori L, Allocca M, Andreotti G, Cubellis M
Int J Mol Sci
. 2019 Aug;
20(17).
PMID: 31454904
A large number of mutations causing PMM2-CDG, which is the most frequent disorder of glycosylation, destabilize phosphomannomutase2. We looked for a pharmacological chaperone to cure PMM2-CDG, starting from the structure...
16.
Furlan F, Eden G, Archinti M, Arnaudova R, Andreotti G, Citro V, et al.
Data Brief
. 2019 Feb;
22:903-908.
PMID: 30723759
The data presented in this article are connected to our research article entitled "D2A-Ala peptide derived from the urokinase receptor exerts anti-tumoural effects in vitro and in vivo" (Furlan et...
17.
Cimmaruta C, Citro V, Andreotti G, Liguori L, Cubellis M, Mele B
BMC Bioinformatics
. 2018 Dec;
19(Suppl 15):433.
PMID: 30497360
Background: Severity gradation of missense mutations is a big challenge for exome annotation. Predictors of deleteriousness that are most frequently used to filter variants found by next generation sequencing, produce...
18.
Citro V, Cimmaruta C, Monticelli M, Riccio G, Mele B, Cubellis M, et al.
Int J Mol Sci
. 2018 Aug;
19(8).
PMID: 30061496
Type I disorders of glycosylation (CDG), the most frequent of which is phosphomannomutase 2 (PMM2-CDG), are a group of diseases causing the incomplete -glycosylation of proteins. PMM2-CDG is an autosomal...
19.
Brasil S, Pascoal C, Francisco R, Marques-da-Silva D, Andreotti G, Videira P, et al.
Int J Mol Sci
. 2018 Apr;
19(5).
PMID: 29702557
Congenital disorders of glycosylation (CDG) are a group of genetic disorders that affect protein and lipid glycosylation and glycosylphosphatidylinositol synthesis. More than 100 different disorders have been reported and the...
20.
Furlan F, Eden G, Archinti M, Arnaudova R, Andreotti G, Citro V, et al.
Peptides
. 2017 Dec;
101:17-24.
PMID: 29273518
D2A-Ala is a synthetic peptide that has been created by introducing mutations in the original D2A sequence, IQEGEEGRPKDDR of human urokinase receptor (uPAR). In vitro, D2A-Ala peptide displays strong anti-tumoural...